The impact of COVID-19 pandemic on colorectal cancer patients: A single-center retrospective study

Yun Xu
Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Dong’an road, 270, Shanghai 200032, China

Zong-Hao Huang
Hospital information Centre, Fudan University Shanghai Cancer Center, Dong’an road, 270, Shanghai 200032, China

Charlie Zhi-Lin Zheng
Mechanical & Aerospace Engineering, University of California, 7400 Boelter Hall Los Angeles, CA 90095, The United States of America

Cong Li
Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Dong’an road, 270, Shanghai 200032, China

Yu-Qin Zhang
Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Dong’an road, 270, Shanghai 200032, China

Tian-An Guo
Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Dong’an road, 270, Shanghai 200032, China

Fang-Qi Liu
Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Dong’an road, 270, Shanghai 200032, China

Ye Xu (yexu@shmu.edu.cn)
Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Dong’an road, 270, Shanghai 200032, China

Research Article

Keywords: public health emergency, colorectal surgery, endoscopy, chemotherapy, clinical management

DOI: https://doi.org/10.21203/rs.3.rs-99183/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: Since December 2019, China has experienced the public health emergency of coronavirus disease, which has expanded globally and is impacting the care of cancer patients. This study evaluated the impact of the pandemic on colorectal cancer (CRC) patients at our center and aimed to share lessons learned with clinics currently experiencing this impact.

Methods: We retrospectively collected data on CRC patients admitted between January 1, 2020 and May 3, 2020; the control group comprised patients admitted between January 1, 2019 and May 3, 2019.

Results: During the pandemic, outpatient volumes decreased significantly, especially among nonlocal and elderly patients, whereas the number of patients who received chemotherapy and surgery were maintained. During the pandemic, 710 CRC patients underwent curative enterectomy. The proportion of laparoscopic surgery was 49.4%, which was significantly higher than the 39.5% patients who received a laparoscopic surgery during the same period in 2019. The proportion of major complication during the pandemic was not significantly different from that of the control group. The mean hospital stay was significantly longer than that of the control group.

Conclusions: CRC patients who are confirmed to be infection-free can receive routine treatment. Using online medical counseling and appropriate identification, treatment and follow-up was effectively maintained. Adjuvant and palliative chemotherapy should not be discontinued. Endoscopic polypectomy, elective, palliative, and multidisciplinary surgeries can be postponed, whereas curative surgery should be performed. For elderly CRC patients, endoscopic surgery and neoadjuvant radiotherapy are recommended.

Background

Since December 2019, China has been experiencing the public health emergency of coronavirus disease (COVID-19) caused by the novel coronavirus (1), which is capable of human-to-human transmission through inhalation (2,3) and fecal–oral transmission (4,5). The rapid spread of the virus has overwhelmed the nation’s health-care system capacity and impacted the management of cancer patients. Cancer patients have been reported to have a high susceptibility for the viral infection, a greater risk for adverse events, and are more prone to deterioration (6,7). Consequently, to avoid hospital-associated transmission of the infection, it was recommended that treatment for most cancer patients should be delayed (8). However, given the risks for cancer progression, delaying treatment remains controversial. A new analysis estimates that the pandemic increased the cancer mortality rate by 20% (9). Thus, within the medical community, improving the management of cancer patients during the pandemic is an urgent priority.

Colorectal cancer (CRC) is one of the most common malignant tumors worldwide (10). As one of the largest departments of colorectal surgery in China, we perform more than 2500 colorectal surgeries annually. To control the spread of the virus, the Shanghai Municipal People’s Government launched a first-level public health response on January 24, 2020 (11). This public health response introduced a new set of rigorous surveillance and safety procedures which, in our clinic, has hampered clinical work involving both the treatment of newly diagnosed CRC patients and the continuing treatment and surveillance of postoperative patients during
outpatient visits. Meanwhile, owing to the potential risk of fecal–oral transmission, surgical treatments for CRC, including colorectal surgery and endoscopy, were severely limited during the pandemic. Moreover, administration of adjuvant chemotherapies to CRC patients was restricted as a result of their immunosuppressive effect (6). Thus, CRC patients are experiencing an unprecedented dilemma.

In response to this dilemma, we have taken specialized measures to avoid viral infections, while ensuring the continued care for cancer patients as much as possible. These measures did not begin to loosen until April, when local infection rates substantially reduced and our clinical practice gradually returned to normal. In this work, we aimed to evaluate the impact of the pandemic on CRC patients in our center to share lessons learned for clinics currently experiencing the impact of this public health emergency.

Methods

Patients

We retrospectively enrolled CRC patients who received treatment at the Fudan University Shanghai Cancer Center during the pandemic (from January 1, 2020 to May 3, 2020), and a control group of patients who received treatment during the same time 2019 (from January 1, 2019 to May 3, 2019).

Data collection

Data on outpatient volume, drug administration, endoscopies, endoscopic treatments, and surgeries were collected from patient charts and compared between the two groups. The pandemic-related changes in CRC patient demographics, clinical care, and surgical safety were evaluated. A major complication was defined as an event requiring surgical, endoscopic, or radiologic intervention. A life-threatening complication was defined as an event requiring intermediate or intensive care and which could result in death (12).

Measures taken in response to public health emergency

Outpatients

In the outpatient clinic, each patient underwent a thorough epidemiological screening to confirm that the patient has had no 1) contact with patients infected with coronavirus, 2) history of travel through areas with severe epidemics, 3) fever, cough, and other symptoms related to COVID-19 over the previous 14 days; 4) abnormalities in routine blood and chest computed tomography (CT) examinations. When these conditions were met, the patient was regarded as free of the coronavirus infection and was thus admitted.

We also established a telemedicine networking platform to facilitate doctor-patient communication and provide outpatient care online. We recommended nonlocal patients to take regular follow-up tests at their local hospitals. These test results were uploaded on our communication platform, and after analyzing these results, we advised patients on whether they should continue follow-ups or undergo treatment. For cases of serious adverse events, we recommended the patients to be treated in our hospital.
Nonsurgical treatments in the outpatient department

We did not restrict adjuvant chemotherapy, whereas intravenous chemotherapy was often replaced with oral chemotherapy in elderly patients. Chemotherapy and immunotherapy were maintained for advanced patients. Neoadjuvant radiotherapy was recommended for patients with rectal cancer.

Endoscopy and endoscopic treatment

Nonurgent endoscopies were delayed and replaced by other imaging modalities, such as CT or magnetic resonance imaging (MRI). If a recurrence or metastasis was found, endoscopies were resumed. Endoscopic polypectomy was postponed.

Surgical treatments

During the pandemic, elective (mainly apothesis after enterostomy), palliative, and multidisciplinary surgeries were postponed. In contrast, curative enterectomy remained routinely performed for resectable CRC patients. For elderly patients with poor general conditions, conservative treatment or palliative surgery could be performed first. Laparoscopic surgery was considered as the first option if available.

Statistical analysis

Continuous variables were reported as mean ± standard deviation. Differences in categorical variables and continuous variables between the groups were analyzed with the chi-square test or Fisher’s exact test and with the Student’s t-test, respectively, using the SPSS version 21.0 software (SPSS, Chicago, IL, USA). Two-tailed p-values less than 0.05 were considered statistically significant.

Results

Outpatients

Outpatient volume during the pandemic and during the same period in 2019 are shown in Figure 1A. During the pandemic, we received 10367 outpatients. The outpatient volume was significantly reduced by 35.6%, when compared with the same period in 2019 (10367 vs. 16087), especially among nonlocal patients (5807 vs. 9961, reduced by 41.7%) (Figure 1B). However, beginning in mid to late April, the outpatient volume gradually recovered. Through the telemedicine networking platform, a total of 3277 patients received online medical counseling. Among them, 2622 cases received follow-up after surgery and 655 cases were newly diagnosed with CRC. Among these 2622 cases, further follow-ups were recommended for 1704 cases, and treatment was recommended for 918. Of the 918 patients, 643 received adjuvant chemotherapy and 275 patients with confirmed or suggested metastasis or recurrence were recommended to be treated at our center. Among the 655 cases of newly diagnosed CRC, 459 were resectable and recommended to be treated in our hospital, while the remaining 196 unresectable cases were recommended to receive chemotherapy, immunotherapy, or radiotherapy.
Chemotherapy in the outpatient department

During the pandemic, 2127 CRC patients received chemotherapy in our department, including 1857 who received intravenous chemotherapy and 270 who received oral chemotherapy. This volume was reduced by 17.1% when compared with the same period in 2019 (2127 vs. 2490) (Figure 2A), mainly among nonlocal patients (1144 vs. 1505, reduced by 24.0%) (Figure 2B). The volume of elderly patients (314 vs. 298) (Figure 2C) and patients who received intravenous chemotherapy (1857 vs. 2153) (Figure 2D), oral chemotherapy (270 vs. 337) (Figure 2E), and immunotherapy (455 vs. 400) (Figure 2F) largely remained at normal levels.

Endoscopy

During the pandemic, 1430 patients underwent endoscopy in our hospital, which was significantly lower than the volume of endoscopy tests conducted during the equivalent period in 2019 (1435 vs. 2785, reduced by 48.5%) (Figure 3A). During the pandemic, volumes of endoscopy tests were lower among nonlocal (727 vs. 1422, reduced by 48.9%) (Figure 3B) and elderly patients (203 vs. 405, reduced by 49.9%) (Figure 3C). During late April, our endoscopy department resumed its normal operations, and the volume of endoscopy tests gradually recovered to normal.

Endoscopic treatment

During the pandemic, 27 patients underwent endoscopic treatment, which was significantly lower than the volume of patients who underwent endoscopic treatment during the same period in 2019 (27 vs. 113, reduced by 76.1%) (Table 1). The number of endoscopy treatments was particularly low between February and March. Treatments for patients who were diagnosed with a colorectal polyp during this period were delayed until April.

Apothesis after enterostomy

During the pandemic, 91 postoperative CRC patients with enterostomy received apothesis. There was a significant decrease in the volume of apothesis between January 2020 to February 2020 (Table 2). The mean hospital stay was 8.8 ± 3.1 days during the pandemic, which was significantly longer than the mean stay (6.8 ± 2.2 days) during the same period in 2019 (t = -5.238, p < 0.001). Delayed surgeries for apothesis were performed between late March and April.

Palliative surgery

During the pandemic, 81 unresectable CRC patients received palliative surgeries (e.g., enterostomy, cytoreductive surgery, palliative enterectomy). The number of palliative surgeries decreased in February 2020 (Table 3). During the pandemic, the mean hospital stay was 11.0 ± 4.3 days, which was significantly longer than the mean hospital stay (9.1 ± 3.1 days) during the same period in 2019 (t = -3.087, p = 0.002).
Multidisciplinary surgery

During the pandemic, 26 CRC patients with peripheral invasion (ovaries, uterus, fallopian tubes, urinary bladder) or liver metastasis underwent multidisciplinary surgeries. The volume of combined procedures decreased from late January to early March, mainly for elderly patients and patients with liver metastasis (Table 4). During the perioperative period, major complications occurred in three (11.5%) patients who received simultaneous resection of the CRC and liver metastasis, which was similar to complication rates in the control group (11.5% vs. 11.1%, $c^2 = 0.245, p = 0.620$). However, the mean hospital stay was $14.3 \pm 4.3$ days during the pandemic, which was longer than the mean hospital stay ($12.3 \pm 3.3$ days) during the same period in 2019 ($t = -2.007, p = 0.049$).

Curative enterectomy

During the pandemic, 710 CRC patients underwent curative enterectomy. The volume of curative enterectomies performed was reduced between late January and late March (Figure 4A), particularly among nonlocal (Figure 4B) and elderly patients (Figure 4C).

Demographic and clinical parameters of patients during the pandemic and the same period in 2019 are compared and demonstrated in Table 5. During the pandemic, the proportion of performed laparoscopic surgeries was 49.4%, which was significantly higher than the proportion (39.5%) during the same period in 2019 ($c^2 = 15.333, p < 0.001$) (Figure 4A, Table 5). In total, 17.3% (123/710) of patients underwent an enterostomy during the pandemic, which was greater than the 13.2% (109/828) who received an enterostomy in the control group ($c^2 = 5.163, p = 0.023$). Among rectal cancer patients, compared with the 17.5% (65/371) of patients who received neoadjuvant radiotherapy in the control group, a greater proportion of patients (79/333; 23.9%) received neoadjuvant radiotherapy during the pandemic ($c^2 = 4.451, p = 0.039$). The rate of major complications did not differ significantly in the perioperative period during the pandemic when compared with that of the control group (3.9% [28/710] vs. 5.1% [42/828]; $c^2 = 1.121, p = 0.290$). The mean hospital stay was $13.2 \pm 4.5$ days, which was significantly longer than the mean hospital stay of $11.0 \pm 4.0$ days during the same period in 2019 ($t = -10.298, p < 0.001$). Both preoperative waiting and postoperative stays were significantly prolonged during the pandemic.

Discussion

The novel COVID-19 pandemic has generated substantial upheaval worldwide and has impaired the ability of the hospitals to diagnose and treat cancer patients. Faced with these challenges, we enacted a series of measures, which have yielded positive results. Given cancer patients’ increased susceptibility to viral infections (6,7), thorough epidemiological screening before outpatient admission ensured the safety of our patients. Beyond the outpatient clinic rational, selection of patients and proper allocation of resources helped us maintain most treatments involving surgery and chemotherapy for CRC patients, while focusing on routine clinical care practices and observing patient responses prevented complication rates in surgeries from increasing. On March 24, the Shanghai Municipal Government downgraded its major public health emergency
first-level response to a second-level response (13). Since then, clinical work has gradually resumed to its original state, and some of the delayed treatments were performed in April.

Since the pandemic, public transport has been restricted, and nonlocal patients have been unable to enter Shanghai for treatment. Among local patients, elderly patients are at a greater risk of infection, and consequently, many have also been unwilling to undergo treatment. This inability for these two groups of cancer patients to receive outpatient treatment is evident in the significant reduction in outpatient volume after the pandemic began, as shown in this study's results. In response, as previously discussed, we established a telemedicine networking platform to provide outpatient care and medical advice online, and only recommended online patients experiencing serious adverse events to be treated at our center. Through such online medical counseling, we effectively maintained treatment and patient follow-ups, thereby reducing mortality, while ensuring the safety of patients.

Adjuvant chemotherapy and palliative chemotherapy have had a great impact on the long-term prognosis of CRC patients. However, the immunosuppressive effects of chemotherapy have made their use controversial (6). At our center, despite restricting the number of patients who received chemotherapy during the pandemic, administration of oral chemotherapy and intravenous immunotherapies were maintained at normal levels. We believe that during the epidemic, adjuvant chemotherapy should not be discontinued, given its importance for ensuring survival of CRC patients. However, intravenous chemotherapy can be discontinued and replaced with oral chemotherapy in elderly patients (14). In addition, we believe that chemotherapy and immunotherapy must be maintained for advanced patients if the patient is confirmed to be free of infection. Otherwise, tumor-related mortality in these patients would increase.

As coronavirus is capable of fecal–oral transmission (4,5), endoscopy might serve as a vector for viral transmission. Consequently, our center discontinued nonurgent endoscopies and endoscopic treatments from February to March, as evident in the 76.1% reduction in the number of patients that underwent endoscopic treatment after the pandemic began. This number has gradually recovered after coronavirus infection rates were significantly reduced in April. Although we believe that endoscopy can be performed selectively during the outbreak, patients must be strictly screened, and only infection-free patients should undergo endoscopy. Moreover, all medical equipment should be strictly disinfected to ensure patient safety. Finally, we suggest that routine endoscopy should only be performed in patients with newly diagnosed colorectal tumors or polyps who are waiting for pathological confirmation. Endoscopies for patients who are routinely monitored through follow-ups can be delayed and replaced by other imaging modalities, such as CT or MRI. If a recurrence or metastasis is found, endoscopies should be resumed. In newly diagnosed patients, endoscopic polypectomy can be postponed if polyps are small or pathologically benign.

During the pandemic, colorectal surgery experienced many problems, including a lack of available blood for transfusions. We further debated the ethical merits of treating elderly patients who may be at a greater risk for viral infection if surgically treated (15-21). Consequently, while more than 700 curative enterectomies were performed during the pandemic, this represented a significant decrease from the number of surgeries performed during the same period in 2019. To ensure the safety of inpatients and medical staff, “infection-free” wards were established. In addition to a proof of admission, only patients and their accompanying guests who presented a proof of stay in Shanghai for 14 days were admitted to the wards.
Through the reasonable triaging of surgical procedures, selection of patients, deployment of medical resources, and careful pre-operation and post-operation observations, we maintained a large volume of surgeries as well as surgical safety. First, we agree that elective surgeries, such as apothesis after an enterostomy, can be delayed (15). Second, palliative surgeries can also be postponed unless the patient experiences serious tumor-related complications that require urgent enterostomy for decompression. Third, owing to the lack of available blood resources, multidisciplinary surgery for CRC with peripheral invasion or liver metastasis is not recommended. In particular, massive bleeding may occur during hepatic surgery. Staged resection combined with chemotherapy is suggested as an alternative. Fourth, curative surgeries should be performed for resectable CRC patients during the pandemic. Close observation and surveillance should be performed both in pre- and post-operation periods, and prolonged hospital stay ensures surgical safety. It is also important to generate a quick workflow to distinguish suggested infected patients from those with postoperative infection and tumor fevers, which has allowed us to identify and treat oncological complications. Last, elderly patients (aged >70 years) are at a greater risk of infection owing to both their cancer and age (17). However, we believe that elderly patients are not a surgical taboo, and regular curative surgery should be performed for those who meet the indications of surgery when strict infection prevention measures are met.

There are no compelling data supporting the notion that respiratory or blood-borne infectious viruses can be transmitted through surgical plumes or aerosolized laparoscopic gas. Laparoscopy is less traumatic compared with laparotomy, which may expedite recovery when compared with an open procedure. Laparoscopy allows for a self-contained operative field, which reduces the spillage of fluids and tissues, thereby decreasing the risk of operative staff to infection. Thus, we recommend the use of laparoscopy during the pandemic.

We recommend prophylactic enterostomy for patients who are at high risk for complications to improve surgical safety in the perioperative period. We also recommend neoadjuvant radiotherapy treatment, in accordance with the European guidelines (22), particularly for elderly patients. Neoadjuvant radiotherapy can contribute to tumor progression control (23) and allow for resource re-allocation, given staffing shortages. Once the pandemic is completed, we will perform curative resection for these patients.

There are some limitations in our research. First, this is a retrospective single-center study. Second, the results of our efforts during the pandemic have yet to be confirmed with longer follow-up times.

**Conclusions**

In conclusion, during the COVID-19 pandemic, outpatient volumes decreased significantly, with the most vulnerable patients, including migrants and elderly patients, worst affected. Nonetheless, we largely maintained the number of patients who received chemotherapy and surgery. Online medical counseling was effective in patient selection and maintaining treatment and follow-up. Adjuvant and palliative chemotherapy for CRC patients should not be discontinued. Elective, palliative, and multidisciplinary surgeries can be postponed, whereas curative surgery should be performed. For elderly CRC patients, endoscopic surgery and neoadjuvant radiotherapy are recommended.

**Abbreviations**
COVID-19: Coronavirus disease; CRC: Colorectal cancer; CT: Computed tomography; MRI: Magnetic resonance imaging

Declarations

Ethics approval and consent to participate

All examinations and treatments were conducted at the Fudan University Shanghai Cancer Center, Shanghai, China, and were in accordance with the Declaration of Helsinki. This study was approved by the Ethics Committee of the Fudan University Shanghai Cancer Center. Written informed consent was obtained from all patients included in this study.

Consent for publication

Not applicable

Availability of data and materials

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests

Funding

This work was supported by the National Natural Science Foundation of China (NO. 81472620), Natural Science Foundation of Shanghai (NO. 16ZR1406700), Science and Technology Commission of Shanghai Municipality Foundation (NO. 18140903702), and the Development Foundation for Shanghai Talents (NO. 2017120).

Authors’ contributions

YX, YX, ZHH, and FQL conceived and designed the study. YX, ZHH, CL, YQZ, and TAG collected and analyzed the data. YX wrote the paper. ZHH, CZZ, YX and FQL reviewed the paper.

Acknowledgements

Not applicable

References

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med.* 2020; 382: 727-33.
2. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *Lancet*. 2020; 395: 514-23.

3. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *N Engl J Med*. 2020; 382:1199-1207.

4. Xu Y, Li X, Zhu B, Liang H, Fang C, Gong Y, et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. *Nat Med*. 2020; 26:502-5.

5. Lin L, Jiang X, Zhang Z, Huang S, Zhang Z, Fang Z, et al. Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection. *Gut*. 2020; 69: 997-1001.

6. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. *Lancet Oncol*. 2020; 21:335-7.

7. Ma J, Yin J, Qian Y, Wu Y. Clinical characteristics and prognosis in cancer patients with COVID-19: A single center’s retrospective study. *J Infect*. 2020; S0163-4453(20)30214-0. doi: 10.1016/j.jinf.2020.04.006.

8. Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. *Ann Oncol*. 2020; 31: 894-901.

9. Wise J. Covid-19: Cancer mortality could rise at least 20% because of pandemic, study finds. *BMJ*. 2020; 369:m1735. doi: 10.1136/bmj.m1735.

10. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. *CA Cancer J Clin*. 2015; 65: 87-108.

11. Shanghai Municipal People’s Government. Shanghai launched a first-level response to resolutely curb the spread of the epidemic. 2020. Available at: [http://www.shanghai.gov.cn/nw2/nw2314/nw32419/nw48516/nw48539/u21aw1423526.html](http://www.shanghai.gov.cn/nw2/nw2314/nw32419/nw48516/nw48539/u21aw1423526.html)

12. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien-Dindo classification of surgical complications: five-year experience. *Ann Surg*. 2009; 250:187-96.

13. Shanghai Municipal People’s Government. Shanghai has decided to downgrade the first-level response to major public health emergencies to second-level response. 2020. Available at: [http://www.shanghai.gov.cn/nw2/nw2314/nw32419/nw48516/nw48545/nw48635/u26aw64496.html](http://www.shanghai.gov.cn/nw2/nw2314/nw32419/nw48516/nw48545/nw48635/u26aw64496.html)

14. Rassy E, Khoury-Abboud RM, Ibrahim N, Kattan C, Assi T, Kattan J. What the oncologist needs to know about COVID-19 infection in cancer patients. *Future Oncol*. 2020; 16:1153-6.

15. Di Saverio S, Pata F, Gallo G, Carrano F, Scorza A, Sileri P, et al. Coronavirus pandemic and colorectal surgery: practical advice based on the Italian experience. *Colorectal Dis*. 2020; 22: 625-34.

16. Chang L, Yan Y, Wang L. Coronavirus Disease 2019: Coronavirus and Blood Safety. *Transfus Med Rev*. 2020; 34: 75-80.

17. Mourey L, Falandry C, de Decker L, Boulahssass R, Carola E, Bengrine Lefevre L, et al. Taking care of older patients with cancer in the context of COVID-19 pandemic. *Lancet Oncol*. 2020; 21: e236.

18. Schwarz L, Tuech JJ. Is the use of laparoscopy in a COVID-19 epidemic free of risk? *Br J Surg*. 2020; 107:e188–.

19. Vigneswaran Y, Prachand VN, Posner MC, Matthews JB, Hussain M. What Is the Appropriate Use of Laparoscopy over Open Procedures in the Current COVID-19 Climate? *J Gastrointest Surg*. 2020:1–6.
20. Falandry C, Filteau C, Ravot C, Le Saux O. Challenges with the management of older patients with cancer during the COVID-19 pandemic. *J Geriatr Oncol*. 2020;1: 747-9.

21. Burki TK. Cancer guidelines during the COVID-19 pandemic. *Lancet Oncol*. 2020; 21: 629-30.

22. Marijnen CAM, Peters FP, Rödel C, Bujko K, Haustermans K, Fokas E, et al. International expert consensus statement regarding radiotherapy treatment options for rectal cancer during the COVID 19 pandemic. *Radiother Oncol*. 2020; 148:213-5.

23. Renehan AG, Malcomson L, Emsley R, Gollins S, Maw A, Myint AS, et al. Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis. *Lancet Oncol*. 2016; 17:174-83.

### Tables

**Table 1.** The number of patients who received endoscopic treatments per month during the pandemic and the same period in 2019.

| Year | January | February | March | April |
|------|---------|----------|-------|-------|
|      | 2019  | 2020  | 2019 | 2020 | 2019 | 2020 |
| ume  | 34  | 9  | 21  | 0  | 31  | 2  |
| patients | 18 (52.9) | 1 (11.1) | 12 (57.1) | 0 | 15 (48.4) | 0 |
| riatent | 4 (11.8) | 0 | 3 (14.3) | 0 | 5 (16.1) | 0 |
| ses  | 31 (91.2) | 7 (77.8) | 19 (90.5) | 0 | 30 (96.8) | 2 (100) |
| at cases | 3 (8.8) | 2 (22.2) | 2 (9.5) | 0 | 1 (4.2) | 0 |
| nt cases | 3 (8.8) | 2 (22.2) | 2 (9.5) | 0 | 1 (4.2) | 0 |

These values are presented as number of patients followed by percentage in parentheses.

**Table 2.** The number of patients who received apotism after enterostomy per month during the pandemic and the same period in 2019.

| Year | January | February | March | April |
|------|---------|----------|-------|-------|
|      | 2019  | 2020  | 2019 | 2020 | 2019 | 2020 |
| te  | 33  | 17  | 17  | 2  | 23  | 25 |
| tients | 29 (87.9) | 15 (88.2) | 13 (76.5) | 0 | 15 (65.2) | 19 (76.0) |
| ents  | 6 (18.2) | 2 (11.8) | 5 (29.4) | 0 | 5 (21.7) | 4 (16.0) |
| at cases | 6 (18.2) | 2 (11.8) | 5 (29.4) | 0 | 5 (21.7) | 4 (16.0) |
| nt cases | 6 (18.2) | 2 (11.8) | 5 (29.4) | 0 | 5 (21.7) | 4 (16.0) |

These values are presented as number of patients followed by percentage in parentheses.

**Table 3.** The number of patients who received palliative surgery per month during the pandemic and the same period in 2019.
**Table 4.** The number of patients who received multidisciplinary surgery per month during the pandemic and the same period in 2019.

| Month | January 2019 | January 2020 | February 2019 | February 2020 | March 2019 | March 2020 | April 2019 | April 2020 |
|-------|--------------|--------------|---------------|---------------|------------|------------|------------|------------|
|       | 21           | 16           | 12            | 7             | 19         | 21         | 25         | 37         |
| Ent.  | 18(85.7)     | 15(93.8)     | 10(83.3)      | 1(14.2)       | 16(84.2)   | 7(33.3)    | 22(88.0)   | 27(73.0)   |
| Posts | 2(9.5)       | 3(18.8)      | 2(16.7)       | 4(57.1)       | 4(21.1)    | 4(19.0)    | 2(8.0)     | 6(16.2)    |
| Cases | 2(9.5)       | 3(18.8)      | 2(16.7)       | 0             | 1(5.3)     | 4(19.0)    | 7(28.0)    | 6(16.2)    |

*These values are presented as number of patients followed by percentage in parentheses.

**Table 5.** Demographic and clinical parameters of patients who receive curative enterectomy at the same period of 2019 and 2020.

| Month | January 2019 | January 2020 | February 2019 | February 2020 | March 2019 | March 2020 | April 2019 | April 2020 |
|-------|--------------|--------------|---------------|---------------|------------|------------|------------|------------|
| IE    | 14           | 7            | 8             | 3             | 5          | 4          | 9          | 12         |
| Patients | 12(85.7) | 5(71.4)     | 5(62.5)       | 2(66.7)       | 4(80.0)    | 2(50)      | 6(66.7)    | 8(66.7)    |
| Posts  | 3(21.4)      | 0            | 0             | 0             | 1(20.0)    | 1(25.0)    | 0          | 2(16.7)    |
| Surgery| 6(42.9)      | 1(14.3)      | 7(87.5)       | 0             | 3(60.0)    | 1(25.0)    | 2(22.2)    | 5(41.7)    |

*These values are presented as number of patients followed by percentage in parentheses.
| parameters                               | 2019 (N = 828) | 2020 (N = 710) | c²/t value | p value |
|-----------------------------------------|----------------|----------------|------------|---------|
| Gender                                  |                |                |            |         |
| Male                                    | 518 (62.6)     | 438 (61.7)     | 0.123      | 0.726   |
| Female                                  | 310 (37.4)     | 272 (38.3)     |            |         |
| Age(years)\(^a\)                       |                |                |            |         |
| <70                                     | 673 (81.3)     | 565 (79.6)     | 0.706      | 0.401   |
| ≥70                                     | 155 (18.7)     | 145 (20.4)     |            |         |
| Area of origin                          |                |                |            |         |
| Local                                   | 212 (25.6)     | 187 (26.3)     | 0.107      | 0.743   |
| Migrant                                 | 616 (74.4)     | 523 (73.7)     |            |         |
| CRC location                            |                |                |            |         |
| Right colon                             | 181 (21.9)     | 166 (23.4)     | 2.336      | 0.311   |
| Left colon                              | 276 (33.3)     | 211 (29.7)     |            |         |
| Rectum                                  | 371 (44.8)     | 333 (46.9)     |            |         |
| Neoadjuvant chemotherapy                |                |                |            |         |
| Received                                | 110 (13.3)     | 115 (16.2)     | 2.596      | 0.124   |
| Neoadjuvant radiotherapy for rectal cancer |            |                |            |         |
| Received                                | 65 (17.5)      | 79 (23.9)      | 4.451      | 0.039   |
| Operative methods                       |                |                |            |         |
| Laparoscopic                            | 327 (39.5)     | 351 (49.4)     | 15.333     | <0.001  |
| Laparotomy                              | 501 (60.5)     | 359 (50.6)     |            |         |
| Transfusion                              |                |                |            |         |
| Received                                | 52 (6.3)       | 45 (6.3)       | 0.002      | 0.963   |
| Enterostomy                             |                |                |            |         |
| Received                                | 109 (13.2)     | 123 (17.3)     | 5.163      | 0.023   |
| Major complication                      |                |                |            |         |
| Occurrence                              | 42 (5.1)       | 28 (3.9)       | 1.121      | 0.290   |
| Preoperative waiting (d.)*              | 3.8±2.8        | 4.8±3.0        | -6.817     | <0.001  |
| Postoperative stay (d.)*                | 7.2±2.8        | 8.4±3.1        | -7.945     | <0.001  |
| Hospital stay (d.)*                     | 11.0±4.0       | 13.2±4.5       | -10.298    | <0.001  |

CRC: colorectal cancer d.: days

*These data are presented as mean ± standard deviation; other values are presented as number of patients followed by percentage in parentheses